Physician profile
Adrian J Yeiser
NPI 1083743884
$1,103.54
in general payments reported to CMS, 2019-2025
10 companies · $55.48 in 2025
The $55.48 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $22.55 · 2021: $75.84 · 2022: $190 · 2023: $369 · 2024: $250 · 2025: $55.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $561.55 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $117.32 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.54 | 2023-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $97.61 | 2019-2022 | |
| Pfizer INC. | $57.81 | 2019-2023 | |
| Boston Scientific Corporation | $55.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.69 | 2023 | Spevigo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Yeiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.